Aspire Biopharma Warrant
ASBPW
29 hedge funds and large institutions have $277K invested in Aspire Biopharma Warrant in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
10% more capital invested
Capital invested by funds: $251K → $277K (+$26.2K)
0% more funds holding
Funds holding: 29 → 29 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1.13% less ownership
Funds ownership: 32.05% → 30.92% (-1.1%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Athos Capital
Hong Kong
|
+$659 |
| 2 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$616 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$4.5K |
| 2 |
CS
Clear Street
New York
|
-$3.28K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.73K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$15 |
| 5 |
FTUS
Flow Traders U.S.
New York
|
-$10 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CA
26
Crossingbridge Advisors
Pleasantville,
New York
| $822 | – | – | – |
|
|
OAC
27
OMERS Administration Corp
Toronto,
Ontario, Canada
| $412 | – | – | – |
|
|
BPA
28
Beacon Pointe Advisors
Newport Beach,
California
| $330 | +$616 | +20,000 | New |
|
|
29
Nomura Holdings
Tokyo,
Japan
| – | -$4.5K | -150,000 | Closed |
|
|
30
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.73K | -57,932 | Closed |
|
|
FTUS
31
Flow Traders U.S.
New York
| – | -$10 | -339 | -2% |
|
ASBPW Hedge Fund Activity: Q4 2025 in Review
29 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q4 2025, worth a combined $277K — up 10% from $251K a quarter earlier.
Fund positioning in ASBPW was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 3 trimmed.
The largest buyer was Athos Capital, opening a new position worth an estimated $659. The largest seller was Nomura Holdings, exiting entirely with an estimated $4.5K sold.
- 29 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $277K of Aspire Biopharma Warrant stock for Q4 2025, up 10% quarter-over-quarter.
- 2 funds opened new Aspire Biopharma Warrant positions in Q4 2025 and 2 closed out, a net change of 0 holders.
- The largest Aspire Biopharma Warrant buyer in Q4 2025 was Athos Capital, an estimated $659 added.
- The largest Aspire Biopharma Warrant seller in Q4 2025 was Nomura Holdings, an estimated $4.5K sold.
Based on aggregated 13F filings for Q4 2025.